1. Home
  2. Labeler Index
  3. Sanofi-aventis U.s. Llc
  4. 0024-5901
  5. Product Images: Praluent

Product Images Praluent

View Photos of Packaging, Labels & Appearance

Table of Contents

  1. Figure 1 - praluent 01
  2. Figure 2 - praluent 02
  3. Figure 3 - praluent 03
  4. Figure 4 - praluent 03a
  5. Figure 5 - praluent 03b
  6. Figure - praluent 04
  7. Figure - praluent 05
  8. Figure - praluent 06
  9. Figure - praluent 07
  10. Figure - praluent 08
  11. Picture A - praluent 09
  12. Figure B - praluent 10
  13. Figure - praluent 11
  14. Figure - praluent 12
  15. Figure - praluent 13
  16. Figure - praluent 14
  17. Figure - praluent 15
  18. Figure - praluent 16
  19. Figure - praluent 17
  20. Figure - praluent 18
  21. Figure - praluent 19
  22. Figure - praluent 20
  23. Figure - praluent 21
  24. Figure - praluent 22
  25. Picture A - praluent 23
  26. Figure B - praluent 24
  27. Figure - praluent 25
  28. Figure - praluent 26
  29. Figure - praluent 27
  30. Figure - praluent 28
  31. Figure - praluent 29
  32. Figure - praluent 30
  33. Figure - praluent 31
  34. PRINCIPAL DISPLAY PANEL - 75 mg/mL Pen Carton - praluent 32
  35. PRINCIPAL DISPLAY PANEL - 150 mg/mL Pen Carton - praluent 33
  36. PRINCIPAL DISPLAY PANEL - 75 mg/mL Syringe Carton - praluent 34
  37. PRINCIPAL DISPLAY PANEL - 150 mg/mL Syringe Carton - praluent 35

Product Label Images

The following 37 images provide visual information about the product associated with Praluent NDC 0024-5901 by Sanofi-aventis U.s. Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Figure 1 - praluent 01

Figure 1 - praluent 01

Figure 2 - praluent 02

Figure 2 - praluent 02

The text describes a table representing data related to the LS mean percent change from the baseline for LDL-C at different time points over 52 weeks for a treatment labeled PRALUENT (N) compared to a placebo treatment. The data shows a considerable decrease in LDL-C levels for the PRALUENT (N) treatment compared to the placebo treatment over the course of 52 weeks.*

Figure 3 - praluent 03

Figure 3 - praluent 03

This appears to be a graph or chart showing the mean percent change of LDL-C before and after a treatment using a drug called PRALUENT compared to placebo. The graph shows that PRALUENT resulted in a decrease in LDL-C levels compared to placebo at various time points over a period of 52 weeks.*

Figure 4 - praluent 03a

Figure 4 - praluent 03a

This text appears to be a graph or chart that shows the LDL-C LS mean percent change from baseline for three groups over a period of 12 weeks, represented by time points on the x-axis. The groups are labeled as "Placebo," "Praluent75 Q2W," and "Praluent 300 Q4W," and have 157, 78, and 312 subjects, respectively. Without a visual, it is difficult to provide further details.*

Figure 5 - praluent 03b

Figure 5 - praluent 03b

This is a table showing the LDL-C LS Mean Percent Change from Baseline over weeks 4, 8, and 12 for a study comparing PRALUENT 150 mg Q2W (N=45) to a placebo (N=24). The results indicate a -70% reduction in LDL-C for the PRALUENT group compared to the baseline.*

Figure - praluent 04

Figure - praluent 04

Figure - praluent 05

Figure - praluent 05

Figure - praluent 06

Figure - praluent 06

Figure - praluent 07

Figure - praluent 07

Figure - praluent 08

Figure - praluent 08

Picture A - praluent 09

Picture A - praluent 09

Figure B - praluent 10

Figure B - praluent 10

Figure - praluent 11

Figure - praluent 11

Figure - praluent 12

Figure - praluent 12

Figure - praluent 13

Figure - praluent 13

Figure - praluent 14

Figure - praluent 14

Figure - praluent 15

Figure - praluent 15

Figure - praluent 16

Figure - praluent 16

Figure - praluent 17

Figure - praluent 17

Figure - praluent 18

Figure - praluent 18

Figure - praluent 19

Figure - praluent 19

Figure - praluent 20

Figure - praluent 20

Figure - praluent 21

Figure - praluent 21

Figure - praluent 22

Figure - praluent 22

Picture A - praluent 23

Picture A - praluent 23

Figure B - praluent 24

Figure B - praluent 24

Figure - praluent 25

Figure - praluent 25

Figure - praluent 26

Figure - praluent 26

Figure - praluent 27

Figure - praluent 27

This is a simple instruction to be followed in a situation where a button has been pressed and needs to be released. The instruction is to release the button immediately.*

Figure - praluent 28

Figure - praluent 28

Figure - praluent 29

Figure - praluent 29

Figure - praluent 30

Figure - praluent 30

Figure - praluent 31

Figure - praluent 31

PRINCIPAL DISPLAY PANEL - 75 mg/mL Pen Carton - praluent 32

PRINCIPAL DISPLAY PANEL - 75 mg/mL Pen Carton - praluent 32

Not available. The given text contains mostly symbols, numerals, and some alphabets that are not intelligible.*

PRINCIPAL DISPLAY PANEL - 150 mg/mL Pen Carton - praluent 33

PRINCIPAL DISPLAY PANEL - 150 mg/mL Pen Carton - praluent 33

Not available. The text contains some words, but they do not make any sense and seem to be randomly arranged.*

PRINCIPAL DISPLAY PANEL - 75 mg/mL Syringe Carton - praluent 34

PRINCIPAL DISPLAY PANEL - 75 mg/mL Syringe Carton - praluent 34

This is a description of Praluent, a medication used as an injection for subcutaneous administration only. It is available in a pre-filled syringe that contains 75mg/mL of the active ingredient alirocumab. The manufacturer of Praluent is Regeneron Sanofi. There is some blurry text at the end that is not readable.*

PRINCIPAL DISPLAY PANEL - 150 mg/mL Syringe Carton - praluent 35

PRINCIPAL DISPLAY PANEL - 150 mg/mL Syringe Carton - praluent 35

The text is a product label of Praluent™ (alirocumab), an injection, containing 150mg/mL of the medication. It recommends the medication for subcutaneous infection only, meant for single-dose use. The label contains information about the manufacturer, dosage, date of infection, and usage instructions.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.